Early Versus Delayed Percutaneous Coronary Intervention for Patients With Non-ST Segment Elevation Acute Coronary Syndrome: A Meta-Analysis of Randomized Controlled Clinical Trials
Abstract
Studies assessing the timing of percutaneous coronary interventions (PCI) in patients with Non-ST segment elevation Acute Coronary Syndromes (NSTEACS) have failed to generate a consensus on how early PCI should be performed in such patients. Purpose: This meta-analysis
Acute coronary syndromes: advances in antithrombotics
Abstract
Contemporary management of acute coronary syndromes ( ACS ) has evolved to include rapid revascularization , potent antithrombotic , and antiplatelets , all of which reduce the risk of ischemic complications . Despite these advances, recurrent ischemic and bleeding event
Switching antiplatelet regimens: alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: a review of the literature and practical considerations for the interventional cardiologist
Abstract
Dual antiplatelet therapy with aspirin plus a P2Y12 receptor inhibitor is the cornerstone of treatment for patients with acute coronary syndrome and in those undergoing percutaneous coronary intervention. Clopidogrel is the most widely used P2Y12 receptor inhibitor. Despite
Pharmacodynamic impacts of proton pump inhibitors on the efficacy of clopidogrel in vivo – a systematic review
Abstract
There is considerable debate about whether concomitant use of proton pump inhibitors ( PPIs ) should be recommended for patients who are prescribed clopidogrel after acute coronary syndrome . Most pharmacokinetic and pharmacodynamic studies in vivo were conducted using small
State of the art in renal denervation
Abstract
Review summarizes available data on renal denervation , including historical background , underlying pathophysiological mechanisms , results of preclinical and clinical studies . Criteria for referral to renal denervation are provided, emphasizing that this procedure should